Could GLP-1 Weight Loss Drugs Cut Beer Sales? Heineken's Warning to British Pubs

Rising use of GLP-1 weight loss drugs may be changing how much alcohol people drink, and brewers are paying attention. This report examines a document Heineken sent to British hospitality venues, alongside responses from other major drinks companies and the scientific research on GLP-1 use and alcohol consumption.

■ Heineken's Warning to Pubs
- What the document told pubs, bars and restaurants about GLP-1 users' drinking habits
- Heineken's suggested adaptations, including smaller servings and low/no-alcohol options
- Heineken's stated plan to monitor these consumer changes into 2027

■ Industry Reactions
- Diageo's view on the manageable impact on brands such as Johnnie Walker and Smirnoff
- Carlsberg's position that current data do not show GLP-1 use driving beer trends
- Context on falling alcohol sales across the US and Europe

■ Evidence on GLP-1 and Alcohol
- Survey findings from users in multiple countries
- Trial results on cravings and consumption among people with alcohol use disorder
- Growing interest in the drugs' potential role in treating alcohol use disorder

This is useful viewing for anyone following consumer goods trends, the alcohol industry, or the wider ripple effects of GLP-1 drugs. It clarifies which claims are backed by data and which remain unconfirmed, helping viewers form their own view of where alcohol demand may be heading.